Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial
Bibliographic record
Abstract
Synopsis• Deucravacitinib an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved by the US Food and Drug Administration for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy 1 -Uniquely binds to the regulatory domain rather than to the catalytic domain where Janus kinase 1/2/3 inhibitors bind 2,3 (Figure 1)• In the global, 52-week, phase 3 POETYK PSO-1 trial (NCT03624127), deucravacitinib was significantly more effective than placebo or apremilast in the treatment of moderate to severe plaque psoriasis 4 -Clinical responses were maintained through 52 weeks 5• Response rates for the coprimary endpoints, ≥75% reduction from baseline in Psoriasis Area and Severity Index (PASI 75) and static Physician's Global Assessment score of 0 (clear) or 1 (almost clear) with a ≥2-point improvement from baseline (sPGA 0/1) at Week 16, were superior with deucravacitinib regardless of prior exposure to biologics, systemic nonbiologics, and/or phototherapy 6• The 2-year efficacy and safety of deucravacitinib in the POETYK long-term extension trial was consistent with Weeks 0-52 of the POETYK PSO-1 and PSO-2 trials 7Objective• The aim of the current analysis was to evaluate the impact of prior treatment on PASI 75 and sPGA 0/1 responses through Week 52 in patients from POETYK PSO-1 who were randomized to deucravacitinib and in those who crossed over from placebo to deucravacitinib at Week 16 Methods• The study design for POETYK PSO-1 is illustrated in Figure 2 • Eligible patients were ≥18 years of age with moderate to severe plaque psoriasis (ie, PASI ≥12, sPGA ≥3, body surface area involvement ≥10% at baseline)• Patients who previously received phototherapy, systemic treatment, and/or biologic treatment were required to complete washout periods ranging from 4 weeks to 6 months before study entry, depending on the treatment
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.006 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".